Company: ARWR
Filing Date: 2025-01-29
Form Type: ARS
Source: 0001628280-25-002866
Chunk: 19

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-01-29
Form: ARS
Chunk 19
---
 Biologically cleavable linkers 2036 LDLR targeting 2028 Muscle delivery platform 2041 Peptide targeting (CPP-Arg) 2028 Peptide targeting (YM3-10H) 2032 Physiologically labile linkers 2036 PK/PD lipid modifiers 2041 RNAi agent design (5′-phosphate mimic) 2037 Targeting groups (Galactose derivative ligands) 2037 Targeting groups (Galactose derivative trimer-PK) 2031 Targeting groups (αvβ3/αvβ5 integrin) 2034, 2038, 2039 Targeting groups (αvβ6 integrin) 2037, 2038, 2041 Transferrin targeting 2028 Trialkyne linkers 2039 Hydrodynamic delivery Third iteration 2024 *Assuming issuance of any pending patent applications, and excluding any patent term adjustments or patent term extensions. The RNAi and drug delivery patent landscapes are complex and rapidly evolving. As such, the Company may need to obtain additional patent licenses prior to commercialization of its candidates. Please see “Risk Factors” in Part I, Item 1A of this Annual Report on Form 10-K. Acquisition of Assets from Novartis On March 3, 2015, Novartis and the Company entered into an Asset Purchase and Exclusive License Agreement (the “RNAi Purchase Agreement”) pursuant to which the Company acquired Novartis’s RNAi assets and rights thereunder. Pursuant to the RNAi Purchase Agreement, the Company acquired or was granted a license to certain patents and patent applications owned or controlled by Novartis related to RNAi therapeutics, was assigned Novartis’s rights under a license from Alnylam Pharmaceuticals, Inc. (“Alnylam”) (the “Alnylam-Novartis License”) and acquired a license to certain additional Novartis assets (the “Licensed Novartis Assets”). The patents acquired from Novartis include multiple patent families covering delivery technologies and RNAi-trigger design rules and modifications. The Licensed Novartis Assets include an exclusive, worldwide right and license, solely in the RNAi field, with the right to grant sublicenses through multiple tiers under or with respect to certain patent rights and know how relating to delivery technologies and RNAi- trigger design rules and modifications. Under the assigned Alnylam-Novartis License, the Company acquired a worldwide, royalty-bearing, exclusive license with